AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04116099 — intervention group
Intervention type: OTHER
Intervention: Conservative care
Description: May include graduated compression, MLD performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
Study NCT04116099 — intervention group
Intervention type: DEVICE
Intervention: Flexitouch Plus
Description: Flexitouch Plus treatment.
Study NCT06042374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Core Stabilization Training
Description: The Progressive Core Stabilization Training was applied to study group as a group exercise with 5-10 athletes which was planned in the form of 3 days/week for a total of 9 weeks and 27 sessions. A session consisted of warm-up, core stabilization (30-40 min.), and cool-down exercises. During the training period, exercise volume, degree of difficulty, additional weight, and level of instability (contralateral limb movements and reduction of the support surface, etc.) for each exercise were incrementally increased in four steps.
Study NCT06042374 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Core Strengthening Exercises
Description: The athletes included in the CG performed only Standard Core Strengthening Exercises which is the first phase of the Progressive Core Stabilization Training on fixed surfaces (i.e. without pads and balls, with a flat floor and a bench) for 3 days/week and totally 9-week.
Study NCT02868892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2
Study NCT01012908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Norzyme - Bergamo
Description: 2 - 8 tablets per day.
Study NCT01012908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creon
Description: 2 - 8 tablets pet day
Study NCT02131844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitated early mobilization
Description: Participants randomized to this group, in addition the preoperative education (usual care), will have early mobilization facilitated by a trained health professional. This health professional will: (1) visit the participant on the day of surgery to reinforce mobilization goals and assist with transfer to a chair and (2) visit the participant three times per day starting from POD 1 to reinforce mobilization goals and walk with the participant (at least the length of the hallway). Targeted walking distances will increase according to the participant's tolerance. This intervention will be undertaken until POD 3 or hospital discharge, whichever comes first.
Study NCT02131844 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants randomized to this group will receive instructions about postoperative mobilization in a preoperative education session and will receive a booklet describing mobilization goals for each POD (sit in a chair for 2 hours on the day of surgery, stay out of bed for at least 6 hours/day from POD 1 until hospital discharge)
Study NCT04378777 — intervention group
Intervention type: PROCEDURE
Intervention: Biological sample collection
Description: During patient hospitalization: Nasal secretion samples by nasal swabs (for non-intubated patients), whole blood (blood draw/phlebotomy) and sputum secretions by endotracheal aspiration (for intubated patients) will be obtained to proceed with immunologic analysis of samples. DNA will be collected from whole blood at enrollment for genetic analysis (e.g., genome-wide association study \[GWAS\]). After hospital discharge: Collection of biologic samples (involving nasal swabs and blood draw/phlebotomy) will occur up to 12 months.
Study NCT01435044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0938
Description: GS-0938 300 mg (3 × 100 mg tablets) administered orally once daily
Study NCT01435044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT01435044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match sofosbuvir
Description: Placebo to match sofosbuvir administered orally once daily
Study NCT01435044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GS-0938
Description: Placebo to match GS-0938 administered orally once daily
Study NCT02836613 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Galcanezumab
Description: Administered SC
Study NCT02836613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study NCT02276378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan low
Study NCT02276378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan low
Study NCT02276378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan high
Study NCT04378777 — intervention group
Intervention type: PROCEDURE
Intervention: Data Collection: Clinical Care Assessments
Description: Baseline data and assessments obtained as part of ongoing clinical care will be collected throughout hospitalization for COVID-19. After hospital discharge, clinical status and activity assessments will occur up to 12 months.
Study NCT02984462 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous Akin osteotomy
Description: The act to AKIN is osteotomy in percutaneous; This technique can be performed with or without fixation, and both methods make reference in the literature. With fixation method to get rid of the risk of loss of the surgical reduction of the misalignment, but requires an additional surgical procedure marked by the implementation of a percutaneous cannulated screw on part of the osteotomy. Without fixing method allows to get rid of this gesture, and risk a possible annoys by osteo-synthesis material. Surgical dressings of surgery of hallux valgus allow to keep the reduction for 15 days. Both techniques give excellent results and are performed in our service of routinely.
Study NCT02252367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil 5 mg once daily for 12 weeks.
Study NCT02252367 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily for 12 weeks.
Study NCT02928952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-STRIDE
Description: Mindful Stress Reduction in Diabetes Education- mindfulness training with home practice will be introduced as part of diabetes education
Study NCT00719199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-2055
Description: SC weekly injections
Study NCT00719199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: given weekly through intravenous administration. Cycle 1 Day 1 dose given at 400mg/m2, all subsequent doses given at 250 mg/m2.
Study NCT00719199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Given day 1 of each cycle
Study NCT04586491 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oral care protocol
Description: Oral care protocol
Study NCT03216993 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units
Study NCT03216993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol care
Description: Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
Study NCT02100384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-implant maintenance
Description: The peri-implant maintenance will be performed by two experienced Registered Dental Hygienists with titanium scalers or ultrasonic instrumentation
Study NCT01755169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).
Study NCT01223820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: 5x nasal application in one day, 1 hour between each application
Study NCT00675935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fall Prevention Tool Kit prototype using a randomized design
Description: Based on the results from Phase 1, Phase 2 and consistent with the literature that suggests that multifaceted, tailored interventions are most effective against inpatient falls, the FPTK prototype will be comprised of two interrelated components 1) The Fall Risk Alert and Communication Plan (translates an individual patient's fall risk assessment into a decision support intervention that communicates fall risk status to team members.) and 2) The Patient Safety Plan of Care PSPOC (translates an individual patient's fall risk assessment into a decision support intervention that creates a tailored evidence-based plan of care). The goal of the FPTK Intervention is to communicate risk status and recommended tailored discipline specific-interventions to prevent falls.
Study NCT02907047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tourniquet inflated
Study NCT02907047 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: tourniquet not inflated
Study NCT01755169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00900003 — intervention group
Intervention type: GENETIC
Intervention: protein analysis
Description: Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival. The markers targeted are proteins secreted by cancer cells and/or cancer associated cells.
Study NCT00900003 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pancreatic cancer population.
Study NCT04539470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efmarodocokin Alfa
Description: Efmarodocokin Alfa will be administered intravenously (IV) per the dosage specified in each dose escalation cohort.
Study NCT01360996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg DRSP/20 μg EE
Description: 1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
Study NCT02537678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care TF-CBT
Description: Stepped Care TF-CBT: Patients will receive Step One: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together),60, 61 scheduled weekly phone meetings (15 minutes), and information from the Stepping Together website and the National Center for Childhood Traumatic Stress website (via web or paper for those without access). Children who do not meet responder status will receive Step Two: 9 (1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks
Study NCT02537678 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard TF-CBT
Description: Standard TF-CBT: Patients will receive 12 (1.5 hr.) standard weekly in-office therapist-directed sessions (2 additional weeks allow for scheduling difficulty). TF-CBT includes child, parent and conjoint parent-child sessions addressing the 10 core trauma treatment components of TF-CBT (e.g., parenting skills, affect modulation, cognitive coping, trauma narrative, etc.).
Study NCT03806244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative acquisition (robotic c-Arm) of images
Description: Conventional laparoscopic colorectal oncologic resection is performed. During the procedure, the operator will identify previously defined anatomical landmarks, point them with an instrument tracked by the navigation system and the accuracy of the stereotactic navigation system will be calculated by comparing the surgical anatomical point and its correspondent on the images of the navigation platform.
Study NCT02735213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 577-MPL
Description: 9 spots multispot micropulse mode(without spacing between the spots),160 um spot size, 0.2 second duration, 5% duty cycle(ON time 0.1ms + OFF time 1.9ms), and 250\~400 milliWatts of power(50% threshold power),150\~200 spots, the laser area is the corresponding leakage on mid-phase FA and around leakage.
Study NCT02735213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TLT
Description: contimuous wave,100um spot size, 0.05 seconds duration, 55\~60 milliwatts of power, 18\~27 spots,the laser area is the corresponding leakage on mid-phase FA.
Study NCT00222105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Doxil 40 mg/m2 IV day 1
Study NCT03985865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intragastric quinine hydrochloride
Description: A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 10 µmol of quinine hydrochloride per kg body weight was administrated into the stomach.
Study NCT03985865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intragastric denatonium benzoate
Description: A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 1 µmol of denatonium benzoate per kg body weight was administrated into the stomach.
Study NCT03985865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intragastric placebo
Description: A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 0.1 ml of water (placebo) per kg body weight was administrated into the stomach.
Study NCT02276378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan high
Study NCT02276378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Study NCT02276378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Study NCT02276378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Japanese meal
Study NCT03627611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxin
Description: 3 months
Study NCT03627611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: 3 months
Study NCT04543370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edasalonexent 2000 mg TID
Description: CAT-1004 capsules
Study NCT04543370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 2 MG/ML
Description: 2 mg/ml syrup
Study NCT02195011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
Study NCT04543370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort 36Mg Tab
Description: 36 mg tablets
Study NCT01169181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMES + brain stimulation
Description: Stroke survivors with plegia of affected upper extremity receive either AMES + rTMS or AMES + tDCS.
Study NCT03741205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPEAC System
Description: Surface Electromyography (sEMG) based seizure monitoring and alerting system
Study NCT02498730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interval Training
Description: High Intensity Interval Training at 100% VO2Max
Study NCT02498730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Training
Description: Continuous Stimulous at 60% VO2Max
Study NCT03985865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraduodenal quinine hydrochloride
Description: A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 10 µmol of quinine hydrochloride per kg body weight was administrated into the duodenum.
Study NCT03985865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraduodenal denatonium benzoate
Description: A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 1 µmol of denatonium benzoate per kg body weight was administrated into the duodenum.
Study NCT03985865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intraduodenal placebo
Description: A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 0.1 ml of water (placebo) per kg body weight was administrated into the duodenum.
Study NCT01534520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intravaginal insertion of 4mL 2% lidocaine gel
Study NCT01534520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: KY Jelly
Study NCT04742283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-126 Ophthalmic Solution 0.002% QD
Description: DE-126 Ophthalmic Solution QD evening and Vehicle QD Morning
Study NCT04742283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate Ophthalmic Solution 0.5% BID
Description: Timolol Maleate Ophthalmic Solution BID (morning and evening)
Study NCT00304603 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No treatment was given to the patients as this is an observational study.
Study NCT02909478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant+Tropisetron
Description: Patients will receive the chemotherapy drugs oxaliplatin,leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus Tropisetron (5mg IV of day1)
Study NCT02909478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone+Tropisetron
Description: Patients will receive the chemotherapy drugs oxaliplatin, leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~Dexamethasone (10 mg IV on day 1 and 5 mg IV days 2, 3) plus Tropisetron (5mg IV of day1)
Study NCT03223961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPREX
Description: 60 000 U/week for at least 12 weeks
Study NCT03265522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ThinkMed resource at baseline
Description: The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline.
Study NCT03976869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594
Description: During treatment period, AZD7594 (360 µg per day) will be administered as oral inhalation via dry powder inhaler or DPI (SD3FL inhaler).
Study NCT00782587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemophase
Description: 40 mg mitomycin with 800,000 U rHuPH20 total volume of 40 mL instilled
Study NCT03265522 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care Control
Description: Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 6 month study visit (i.e. delayed intervention).
Study NCT03265522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ThinkMed resource (staged)
Description: This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian
Study NCT01920035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroCool (Local cooling/hypothermia)
Description: These patients will receive the UroCool device which will be inserted just prior to RARP surgery. The UroCool device will be used to effect localized cooling/hypothermia of the pelvic region prior to and during RARP surgery. It will be removed at the end of surgery.
Study NCT03889301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-E Video
Description: The E-E video was developed by the research team and chronicles the story of Ana who while enjoying coffee with two family members, shares her challenges with depression and her successful outcome with therapy. The video utilizes the genre of the telenovela which creates an entertaining environment where the audience is captivated by the content and absorbs the messages portrayed.
Study NCT03889301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discussion
Description: Structured psychoeducation and pamphlet about anxiety and depression.
Study NCT02969603 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging as reference
Study NCT02969603 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance combined with Positron Emission Tomography
Description: Comparison with MRI only, to assess muscular activity, creation of anatomic images of muscle activity and resolution of metabolic activity distribution within exercising skeletal muscle
Study NCT03396757 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard strategy
Description: RRT is initiated within 12 hours after documentation of serum urea concentration >40 mmol/l and/or an oliguria/anuria for more than 72 hours. The timing of its initiation will be recorded and RRT will continue until criteria for cessation are observed. This arm corresponds to the delayed strategy in the published AKIKI trial (NEJM 2016),